Author

Gurunath Chavan

Observed name: GURUNATH CHAVAN

Institution: Lupin Pharmaceuticals (India)

Observed institution: Lupin Pharmaceuticals (India)

ORCID: 0009-0008-1420-9645

Observed ORCID: 0009-0008-1420-9645

OpenAlex ID: A5137533683

Real-World Prescribing Patterns and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Empagliflozin-Sitagliptin-Metformin Fixed-Dose Combination Therapy

2026 · Balaji T Naik, Shrimant Y, et al. · Cureus

26-PUB: Real-World Preference for Triple Fixed-Dose Combination of Empagliflozin, Sitagliptin, and Metformin by Various Health Care Specialist in India: Real Impossible Trio

2026 · PRADIP MATE, GURUNATH CHAVAN · Diabetes

Role of cetuximab in recurrent and/or metastatic head and neck cancer (R/M-HNC) in the era of immunotherapy: Consensus from India

2026 · M V Chandrakanth, Rajat Bajaj, et al. · South Asian Journal of Cancer

Cetuximab in platinum-ineligible patients with locally advanced squamous cell carcinoma of the head and neck: Consensus from India

2025 · Agarwala Vivek, Aggarwal Shyam, et al. · Indian Journal of Cancer

Works count: 4

Citation count:

H-index:

I10-index: